Q1 Earnings Forecast for XENE Issued By William Blair

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research report issued on Friday, February 28th. William Blair analyst M. Minter forecasts that the biopharmaceutical company will post earnings of $0.00 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Other equities analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Stock Down 3.4 %

XENE stock opened at $37.02 on Monday. The stock has a market capitalization of $2.82 billion, a P/E ratio of -13.13 and a beta of 1.20. The firm has a 50-day simple moving average of $39.27 and a 200-day simple moving average of $40.33. Xenon Pharmaceuticals has a 52 week low of $33.27 and a 52 week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 487 shares during the period. Advisors Asset Management Inc. grew its position in Xenon Pharmaceuticals by 3.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 13,592 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 493 shares during the last quarter. Occudo Quantitative Strategies LP increased its stake in Xenon Pharmaceuticals by 5.8% in the 4th quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company’s stock valued at $448,000 after buying an additional 630 shares during the period. Geode Capital Management LLC raised its position in Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company’s stock worth $2,726,000 after buying an additional 720 shares during the last quarter. Finally, KBC Group NV raised its position in Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders sold 57,492 shares of company stock valued at $2,334,969 in the last ninety days. Insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.